Como citar este artigo
Mungmunpuntipantip R, Wiwanitkit V. . Arq. Bras. Cardiol. 2022;119(6):1006-7.
Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj. . Arq. Bras. Cardiol., v. 119, n. 6, p. 1006-1007, nov. 2022.
Mungmunpuntipantip, R., & Wiwanitkit, V. (2022). . Arq. Bras. Cardiol., 119(6), 1006-1007.
Mungmunpuntipantip, Rujittika and Wiwanitkit, Viroj. . Arq. Bras. Cardiol. [online]. 2022, vol. 119, n. 6, [cited 2025-09-08], pp.1006-1007. Available from: <https://abccardiol.org/article/11719/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.